For US Healthcare Professionals Only

Headline h1

Headline h2

Headline h3

Headline h4

Headline h5
Headline h6

Paragraph tag

Layout component with variables

<Layout site="advsm" />

Site variables: advsm, gist, ism

Use case: use the variable to target class and or swap out header/footer

Colors

//ISM/AdvSM/GIST
$navy
$deep-turquoise
$sky-blue
$light-blue
$yellow
$light-yellow
$gray
$dark-gray
$black
$white

//AdvSM
$brown
$spring-green

Background Colors

.bg-sky-blue-grad
.bg-navy
.bg-deep-turquoise
.bg-sky-blue
.bg-light-blue
.bg-faint-blue
.bg-yellow
.bg-light-yellow
.bg-gray
.bg-black
.bg-white
.bg-brown
.bg-spring-green

Button

<Button copy="Contact Us" url="/" buttontheme="yellow-sky-blue-navy" texttransform="uppercase"/>

Contact Us
Contact Us
Contact Us
Contact Us


<Button copy="Download" url="/sample/" type="download" target="_blank" buttontheme="yellow-white-deep-turquoise" texttransform="none"/>

Download

CTA Enrollment

<CTAEnroll copy=With AYVAKIT, your patients have access to the YourBlueprint<sup>®</sup> patient support program. Enrollment is quick and easy. btncopy=Enroll Your Paitent buttontheme="yellow-navy-sky-blue" url="/sample/" />

With AYVAKIT, your patients have access to the YourBlueprint® patient support program. Enrollment is quick and easy.


<CTAEnroll copy="With AYVAKIT, your patients have access to the YourBlueprint® patient support program. Enrollment is quick and easy." btncopy="Enroll Your Paitent" buttontheme="yellow-sky-blue-deep-turquoise" btntexttransform="uppercase" url="/sample/" />

With AYVAKIT, your patients have access to the YourBlueprint® patient support program. Enrollment is quick and easy.


CTA Basic

<CTABasic copy="Learn about the safety of AYVAKIT evaluated in the EXPLORER and PATHFINDER clinical trials." ctatheme="yellow-navy-white" btncopy="Go To Safety" stripes="stripes-navy-sky-blue" btntexttransform="uppercase" buttontheme="sky-blue-navy-yellow" url="/sample/" />

icon triangle down navy
Learn about the safety of AYVAKIT evaluated in the EXPLORER and PATHFINDER clinical trials.


<CTABasic copy=Explore the safety of AYVAKIT btncopy=Safety ctatheme="yellow-sky-blue-navy" buttontheme="yellow-sky-blue-deep-turquoise" btntexttransform="uppercase" url="/sample/"/>

icon triangle down navy
Explore the safety of AYVAKIT


<CTABasic copy=Explore the safety of AYVAKIT btncopy=Resources ctatheme="sky-blue-yellow-navy" stripes="stripes-yellow-navy" buttontheme="white-sky-blue-navy" btntexttransform="uppercase" url="/sample/" />

icon triangle down navy
Explore the safety of AYVAKIT


CTA Advanced

<CTAAdvanced copy=Access additional resources for you and your patients btncopy=Efficacy ctatheme="light-blue-deep-turquoise" icon=iconGraph buttontheme="yellow-white-deep-turquoise" btntexttransform="uppercase" url="/sample/" />


Access additional resources for you and your patients
Access additional resources for you and your patients
Access additional resources for you and your patients


Access additional resources for you and your patients

Special Header

<div className="sp-header bg-yellow center" > <h5 className="navy">Product Order Sheet</h5> </div>

Product Order Sheet

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Adipiscing elit pellentesque habitant morbi tristique senectus et. Arcu ac tortor dignissim convallis aenean et.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Adipiscing elit pellentesque habitant morbi tristique senectus et. Arcu ac tortor dignissim convallis aenean et.



Table chart

Time on therapyMonitoring planTreatment plan
Prior to initiationPerform platelet count.AYVAKIT is not recommended in Advanced SM patients with platelet counts <50 x 109/L.
First 8 weeksPerform platelet count every 2 weeks regardless of baseline platelet count.

If platelet count <50 x 109/L occurs, interrupt AYVAKIT until platelet count is 50 x 109/L, then resume at reduced dose.

If platelet counts do not recover above 50 x 109/L, platelet support may be necessary.

After 8 weeksMonitor platelet counts:
  • Every 2 weeks if values are <75 x 109/L (or more frequently as clinically indicated)
  • Every 4 weeks if values are 75-100 x 109/L
  • As clinically indicated if values are >100 x 109/L

Accordion

<Accordion title="Accordion header"><p>Accordion content</p></Accordion>

Accordion header
Down Arrow


TabbedContent



Tab 1 content



Form

<Form site="ism" >

NO TYPE DEFINED

All fields required unless otherwise noted.

By submitting this form:

  • I confirm that I am a US healthcare professional and agree to receive information about AYVAKIT for ISM and related disease state information. I can opt out from such communications by replying “Unsubscribe” to any email.
  • I acknowledge that I have read and agree to Blueprint Medicines' Terms of Use.

To learn more about Blueprint Medicines' privacy practices, including how we process, share, and protect your Personal Information, please read our Privacy Notice.

Oops! We're missing key information we need to connect with you.

Submit


<Form site="advsm" >

Sign up to receive updates on AYVAKIT for Advanced SM and connect with a representative

All fields required unless otherwise noted.

To learn more about Blueprint Medicines' privacy practices, including how we process, share, and protect your Personal Information, please read our Privacy Notice.

Oops! We're missing key information we need to connect with you.

Submit


<Form site="gist" >

Connect with Blueprint Medicines

For more information about AYVAKIT and to speak to a representative from Blueprint Medicines, please complete this form:

All fields required unless otherwise noted.

This is a required field.

By submitting this form, I acknowledge that I have read and agree to Blueprint Medicines' Terms of Use.

To learn more about Blueprint Medicines' privacy practices, including how we process, share, and protect your Personal Information, please read our Privacy Notice.

Oops! We're missing key information we need to connect with you.

Submit